Bucking Biosimilar Threat, Roche Sees Further Growth
Many new and pipeline products were highlighted at London meeting – but no word on Spark Therapeutics deal. New products will have high profit margins.
You may also be interested in...
Roche presented another strong quarterly performance and raised its outlook again for the full year, as sales continued to be driven in the third quarter by its portfolio of new medicines. It still believes its delayed takeover of Spark Therapeutics will happen by year-end.
Bill Anderson says Roche has scrapped budgets and improved productivity and re-energized teams. But is it too good to be true?
Promising Phase II data mean it could be third time lucky for Roche in disease with no approved treatments.